Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease.

Carrat F, Seksik P, Colombel JF, Peyrin-Biroulet L, Beaugerie L; CESAME Study Group..

Aliment Pharmacol Ther. 2017 Feb;45(4):533-541. doi: 10.1111/apt.13897. Epub 2016 Dec 19.

PMID:
27995656
2.

Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

Bourrier A, Carrat F, Colombel JF, Bouvier AM, Abitbol V, Marteau P, Cosnes J, Simon T, Peyrin-Biroulet L, Beaugerie L; CESAME study group..

Aliment Pharmacol Ther. 2016 Jan;43(2):252-61. doi: 10.1111/apt.13466. Epub 2015 Nov 9.

PMID:
26549003
3.

Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer.

Beaugerie L, Carrat F, Colombel JF, Bouvier AM, Sokol H, Babouri A, Carbonnel F, Laharie D, Faucheron JL, Simon T, de Gramont A, Peyrin-Biroulet L; CESAME Study Group..

Gut. 2014 Sep;63(9):1416-23. doi: 10.1136/gutjnl-2013-305763. Epub 2013 Oct 25.

PMID:
24162591
4.

Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease.

Sokol H, Beaugerie L, Maynadié M, Laharie D, Dupas JL, Flourié B, Lerebours E, Peyrin-Biroulet L, Allez M, Simon T, Carrat F, Brousse N; CESAME Study Group..

Inflamm Bowel Dis. 2012 Nov;18(11):2063-71. doi: 10.1002/ibd.22889. Epub 2012 Jan 23.

PMID:
22271569
5.

Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.

Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, Carbonnel F, Colombel JF, Dupas JL, Godeberge P, Hugot JP, Lémann M, Nahon S, Sabaté JM, Tucat G, Beaugerie L; Cesame Study Group..

Gastroenterology. 2011 Nov;141(5):1621-28.e1-5. doi: 10.1053/j.gastro.2011.06.050. Epub 2011 Jun 25.

PMID:
21708105
6.

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, Hébuterne X, Cortot A, Bouhnik Y, Gendre JP, Simon T, Maynadié M, Hermine O, Faivre J, Carrat F; CESAME Study Group..

Lancet. 2009 Nov 7;374(9701):1617-25. doi: 10.1016/S0140-6736(09)61302-7.

PMID:
19837455
7.

Five-mm-diameter implants without a smooth surface collar: report on 98 consecutive placements.

Renouard F, Arnoux JP, Sarment DP.

Int J Oral Maxillofac Implants. 1999 Jan-Feb;14(1):101-7.

PMID:
10074759
8.

A revised technique for stage-two surgery in the severely resorbed mandible: a technical note.

Arnoux JP, Papasotiriou A, Weisgold AS.

Int J Oral Maxillofac Implants. 1998 Jul-Aug;13(4):565-8.

PMID:
9714965
9.

Single-tooth anterior implant: a word of caution. Part II.

Arnoux JP, Weisgold AS, Lu J.

J Esthet Dent. 1997;9(6):285-94. Review. No abstract available.

PMID:
9477841
10.

Single-tooth anterior implant: a world of caution. Part I.

Weisgold AS, Arnoux JP, Lu J.

J Esthet Dent. 1997;9(5):225-33. Review. No abstract available.

PMID:
9470571
11.

[Malignant pancreatic endocrine tumor with isolated raising of serum thyrocalcitonin. Secondary appearance of Zollinger-Ellison syndrome].

Benoit R, Metman EH, Bacq Y, Arnoux JP, Fetissof F.

Gastroenterol Clin Biol. 1995 Apr;19(4):450-2. Review. French. No abstract available.

PMID:
7672537

Supplemental Content

Loading ...
Support Center